Jubilant Ingrevia reported a 7% increase in revenue and an 8% rise in EBITDA for Q2’FY26. The Specialty Chemicals segment continues to drive growth, while Chemical Intermediates achieved its highest quarterly sales in six quarters. The company remains focused on innovation and sustainability, aiming to sustain growth in topline and margins.
Q2’FY26 Financial Performance
Jubilant Ingrevia announced its financial results for the second quarter of fiscal year 2026, showcasing steady growth despite challenging market conditions. Key highlights from the announcement include:
- Total Revenue: ₹1,121 Crore, up 7% year-over-year.
- EBITDA: ₹146 Crore, an increase of 8% compared to the previous year.
- Profit After Tax: Increased by 18%.
On a half-yearly basis, the company’s EBITDA grew by 18%, and Profit After Tax surged by 34%.
Segment Highlights
The company witnessed varied performances across its segments:
- Specialty Chemicals: Continued growth momentum, reporting margins above 25%.
- Nutrition & Health Solutions: Steady volume growth, with some pricing pressure on feed-grade vitamins.
- Chemical Intermediates: Achieved highest quarterly revenue and volumes in the last six quarters.
Business Outlook
Looking ahead to the second half of fiscal year 2026, Jubilant Ingrevia anticipates continued growth, fueled by progress in its Specialty Chemicals and Nutrition businesses. The company is on track to start serving its major CDMO order in early 2026 and has broken ground on a new multipurpose plant in Gajraula.
Strategic Initiatives
Jubilant Ingrevia is also focused on sustainability and has successfully commissioned Renewable O2 Power at its Bharuch site. This has increased the company’s renewable power share to 28%. The company is also implementing a Lean savings program, targeting ₹100 crore in annual savings.
Source: BSE
